Cartesian Therapeutics, Inc. — Director's Dealing 2024

Mar 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-03-14

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-14	Common Stock	P	648372	$0.5424	Acquired	30516862	Indirect
2024-03-15	Common Stock	P	537500	$0.5852	Acquired	31054362	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7471625	Direct
Common Stock	86418	Indirect

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.5002 to $0.5600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

F3: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.5326 to $0.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.